Humanigen

THE CYTOKINE STORM COMPANY

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms.

Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.

PRODUCT PIPELINE

- **Lenzilumab™ demonstrated positive results** in a late-stage, fully enrolled, **520 patient Phase 3 clinical trial** for treatment of hospitalized patients with **COVID-19** pneumonia. In May 2021, Humanigen submitted an application for **Emergency Use Authorization (EUA)** for lenzilumab in COVID-19
- **Lenzilumab was selected by NIAID** for a fully **NIH-sponsored 200 patient clinical trial** in combination with Remdesivir for COVID-19
- **Lenzilumab demonstrated positive results** in a case-cohort study published by **Mayo Clinic**
- Humanigen announced **positive data** in a Phase 1b study of lenzilumab in **diffuse large B-cell lymphoma** (DLBCL), with plans to initiate a potential registrational Phase 2 study
- Potential registrational trials are in late-stage planning in **acute GvHD and CMML**
- Potential to **improve efficacy of CAR-T therapies** while reducing serious and potentially life-threatening side effects
- An additional Phase 2 trial has been completed **evaluating lenzilumab in eosinophilic asthma**

Two other pipeline candidates are currently in development for solid tumors, inadequately controlled asthma and other eosinophilic diseases.

- **Ifabotuzumab**: anti-EphA3 monoclonal antibody currently being evaluated in solid tumors
- **HGEN005**: anti-EMR1 monoclonal antibody to be evaluated in severe eosinophilic diseases

PARTNERSHIPS

- Clinical Trial Agreement with **NIAID** in COVID-19
- Exclusive worldwide license agreement with the **University of Zurich** in GvHD
- Worldwide license agreement with the **Mayo Foundation for Medical Education and Research** in CAR-T and viral ARDS
- Clinical Trial Agreement with **IMPACT Group** for aGvHD
- Contract Development and Manufacturing Agreement with **Emergent BioSolutions** for lenzilumab
- Current Good Manufacturing Practice (cGMP) agreement with **Avid Bioservices** to support potential EUA filing
- Manufacturing agreement with **Chime Biologics** to to produce lenzilumab bulk drug substance and drug product

For more information, contact Grace Catlett: **gcatlett@rxmedyn.com**

TEAM

Humanigen, Inc. is led by a senior management team with extensive leadership experience in the biotechnology and pharmaceutical industries.

Chairman & CEO
Cameron Durrant, MD, MBA

Chief Scientific Officer
Dale Chappell, MD, MBA

Chief Operating Officer & Chief Financial Officer
Timothy Morris, CPA

Chief Medical Officer
Adrian Kilcoyne, MD, MBA

Chief Commercial Officer
Edward P. Jordan, MBA

Head of Asia-Pacific Region
Bob Atwill, MBA

Sr. Vice President, Clinical, Medical & Scientific Affairs
Omar Ahmed, PharmD

Sr. Vice President, Investor Relations
Ken Trbovich

Vice President, Finance
Henry Madrid



CONTACT

Humanigen, Inc.
533 Airport Blvd #400
Burlingame, CA 94010, USA
650-243-3100

Investor Relations
ir@humanigen.com

Public Relations
RXMD | gcatlett@rxmedyn.com

Business Development
Bob Atwill | batwill@humanigen.com

Twitter
@humanigen

LinkedIn
linkedin.com/company/humanigen-inc

Facebook
@Humanigen

Website
www.humanigen.com